Search Results
Your search for ,HOW matches 8288 pages
Showing 3101 - 3150A Nobel Laureate’s Road to Research Is Not Without Challenges
The 2019 Nobel Prize for Physiology and Medicine was jointly awarded to three researchers. Their discoveries paved the way for promising new strategies to treat anemia, cancer, and many other diseases. One of the three Nobel Laureates is William G. Kaelin, Jr, MD, who continues his research at his...
International Medical and Radiation Oncologist Balances Cancer Research and Clinical Practice
The Revolutions of 1989 that resulted in the end of communist rule in Central and Eastern Europe and beyond began in Poland. Perhaps if not for that social upheaval, the career of internationally renowned oncologist Jacek Jassem, MD, PhD, would have taken a very different path. Dr. Jassem had fled...
A Lung Cancer Specialist’s Winding Journey From Venezuela to Wisconsin
Lung cancer specialist Narjust Duma, MD, was born and reared in Mérida, Venezuela, a city nestled on a plateau in the Venezuelan Andes. “I’m the daughter of two surgeons. After my parents divorced, I lived with my mother and spent a lot of time at the hospital where she worked. When she was in...
An Early Interest in Cancer Immunology Inspires a Life’s Work in Melanoma
F. Stephen Hodi, MD, Director of the Melanoma Center and the Center for Immuno-Oncology at Dana-Farber/Brigham and Women’s Cancer Center, was born in Framingham and grew up in the town of Acton, a western suburb of Boston. “My dad was an engineer, and I was influenced by puzzle-solving and using...
ASCO’s President Aims to Ensure Equitable Cancer Care for Every Patient
The desire to pursue a career in medicine took root when Lori J. Pierce, MD, FASTRO, FASCO, was a young child visiting family in segregated Ahoskie, North Carolina. She witnessed firsthand the impact the town’s lone African American family physician had on the community. When it came time to...
From the United States to Germany and Back Again to Become ASCO President in 2021–2022
ASCO President-Elect Everett E. Vokes, MD, FASCO, is the John E. Ultmann Professor, Chair of the Department of Medicine, and Physician-in-Chief of University of Chicago Medicine and Biological Sciences. After a journey from the United States to Germany and back again, Dr. Vokes arrived at the...
Reflections of an ASCO President: Science vs Practice
My year as President was a busy one. Aside from continuing my research and directing the activities of the National Surgical Adjuvant Breast and Bowel Project, I was drowned by the vast amount of information that was sent to me by ASCO headquarters. At the onset of my Presidency, I discovered a...
Tribute to Bernard Fisher, MD
Bernard Fisher, MD, who died on October 16, 2019, at the age of 101, is recognized today for his groundbreaking research in breast cancer, which ultimately ended the standard practice of performing the Halsted radical mastectomy, a treatment that had been in place for more than 75 years. His...
Renowned Researcher and Surgeon Helps to Transform Treatment of Breast Cancer
Although ‘paradigm shifts’ are frequently referenced in oncology, these are really few and far between. They occur when new data either partially invalidate previously accepted theory or are at complete odds with the existing paradigm. Moving away from the Halsted radical mastectomy, a standard of ...
Internationally Regarded Cancer Immunologist Did Not Stray Far From Home
Internationally recognized immune-oncology melanoma expert Jedd D. Wolchok, MD, PhD, FASCO, was born and reared in Staten Island, not far from where he would shape his noted career at Memorial Sloan Kettering Cancer Center (MSK) in New York, New York. “I went to Princeton University and, during my ...
Expert in Clinical Trial Methodology Makes His Mark in Genitourinary Cancer
In 2019, at the ASCO Annual Meeting, Ian Tannock, MD, PhD, DSc, FASCO, was honored with the Allen S. Lichter Visionary Award for his contributions to the fields of genitourinary and breast cancers as well as his efforts to optimize clinical trial design. The title of his lecture was “Clinical...
Love of Science, Passion for Research, and Belief in the Power of the Immune System
Steven A. Rosenberg, MD, PhD, FASCO, knew from the start of his medical career that if treatments for cancer were to become curative, research in new therapies would have to move away from the mainstay one-size-fits-all approach of systemic chemotherapy to an innovative, personalized strategy that ...
Love of Science and a Family Tragedy Set the Course for This Breast Cancer Researcher
When oncology luminary Joyce A. O’Shaughnessy, MD, was in her early teens, her youngest sister, Teri, developed acute lymphocytic leukemia at age 5. Dr. O’Shaughnessy, the oldest of four girls, recalled that her sister’s struggle with the disease had a profound effect on her worldview. “Teri went...
Howard A. Burris III, MD, FACP, FASCO, on Highlights of the ASCO20 Virtual Scientific Program
Howard A. Burris III, MD, FACP, FASCO, talks about some of the reports of research developments he is looking forward to and how future conferences could incorporate virtual presentations.
David R. Wise, MD, PhD, on Novel Biomarkers in Prostate Cancer: Is Tissue the Issue?
David R. Wise, MD, PhD, of New York University Perlmutter Cancer Center, summarizes three important studies in prostate cancer: circulating tumor cell count as a prognostic marker of PSA response and progression in metastatic castration-sensitive disease; new phenotypic subtypes; and how...
Geriatric Assessment–Driven Intervention Benefits Older Adults With Cancer
Geriatric assessment–driven interventions—such as physical therapy, nutritional recommendations, and social support, among others—can reduce toxicity due to chemotherapy in adults with cancer aged 65 years and older, according to results from a randomized clinical trial presented as part of ASCO20...
Patients With Cancer Infected With COVID-19 Have More Severe Illness and Higher Mortality Rates Than the General Population
A large cohort study by the COVID-19 and Cancer Consortium evaluating the impact of COVID-19 on patients with cancer has found that all-cause 30-day mortality and severe illness were significantly higher in this population than previously reported in the general population. Mortality and severe...
Introducing The ASCO Post
Over the years I have become increasingly proud of the American Society of Clinical Oncology. I believe that ASCO is unique among specialty societies—at least in the various disciplines of oncology and hematology. Our Society is amazingly democratic (ie, with an independent nominating process and...
New Guidance Released for Oncology Community on Allocation of Limited Resources During the COVID-19 Pandemic
ASCO recently released a set of recommendations to support the oncology community as health-care institutions across the United States face potentially difficult decisions around the allocation of scarce health-care resources during the COVID-19 pandemic. In some geographic areas, the ongoing...
Fundraising to Help Patients and Oncologists During the COVID-19 Pandemic
Conquer Cancer, the ASCO Foundation, is raising money through COVID Impacts Cancer, an emergency campaign to support patients with cancer, cancer care teams, and researchers. This fund will aid in advancing vital cancer research and expanding support for patients and oncology providers during and...
Milestone Memories: Conquer Cancer Researcher Searches for Colorectal Cancer Cures
On her wedding day, a father—who happens to have colorectal cancer—walks his daughter down the aisle. His oncologist, Rona Yaeger, MD, of Memorial Sloan Kettering Cancer Center, helped him mark this milestone. Currently, patients with BRAF-mutant colorectal cancers face a poor prognosis. Dr....
Tips for First-Time Abstract Presenters
The fundamental goal of scientific meetings is to share knowledge and accelerate scientific advances. Investigators use different types of presentations to disseminate and share their valuable work with others in the field. This is an important aspect of promoting their scientific careers. These...
A Long Crusade Against Some of the World’s Most Virulent Diseases for Anthony S. Fauci, MD
The doctor-patient relationship, a time-honored tradition based on trust and cooperation, is critical for vulnerable patients, as they experience a heightened reliance on the physician’s competence, skills, and good will. That same trust is critical on the public health stage, when a nation is...
Brain Cancer Prepared Me for the Isolation and Uncertainty of the COVID-19 Pandemic
The symptoms of low-grade oligodendroglioma first appeared in the summer of 2003, when I was 12, but they were vague enough—mild headaches and occasional weird sensations on my right side—to ignore. In the fall, I tripped and fell during a game of rollerblade hockey with my classmates and started...
The Arc of Therapy—From Cure to Humbling Legacy
The ASCO Post is pleased to reproduce installments of Art of Oncology as published previously in the Journal of Clinical Oncology. These articles focus on the experience of suffering from cancer or of caring for people diagnosed with cancer, and they include narratives, topical essays, historical...
A Daughter of Immigrant Doctors, Nina Kadan-Lottick, MD, MSPH, Chose a Career in Pediatric Oncology
In 2003, Nina Kadan-Lottick, MD, MSPH, established the regional Yale HEROS multidisciplinary research and clinical program for long-term survivors of childhood cancer survivors, which is the first of its kind in Connecticut and one of the first in the United States. She intends the HEROS program to ...
COVID-19 Evidence Accelerator Leverages Real-World Data
The Reagan-Udall Foundation for the U.S. Food and Drug Administration (FDA) in collaboration with Friends of Cancer Research recently announced the COVID-19 Evidence Accelerator, an expansive public-private partnership combining the efforts of academic, government, and private sector organizations...
Paul G. Marks, MD, Visionary Leader of Memorial Sloan Kettering Cancer Center, Dies at 93
In 1980, Paul G. Marks, MD, became the President and Chief Executive Officer of Memorial Sloan Kettering Cancer Center (MSK), the oldest and largest private cancer center in the world. Over his 19-year reign, he is credited with setting MSK on a more scientific course by encouraging innovative...
Researcher and Leader in Cancer Center Administration, John W. Yarbro, MD, PhD, Dies at 88
Most who leave a mark in life are noted for a single contribution; few are remembered for the breadth of their contributions. Such a man was John W. Yarbro, MD, PhD, who, near the end of his rich life, stepped foot on Antarctica, completing his desire to have visited all of the world’s seven...
Champion in Geriatric Oncology, Rosemary Yancik, PhD, Dies at 86
Rosemary Yancik, PhD, a medical sociologist, was best known for her talent of bringing a group of experts together who shared her interests in improving the prevention and management of cancer in elderly patients. She served many years at the National Institutes of Health in both the National...
What Have I Learned in More Than Half a Century in Cancer Medicine?
My journey in cancer medicine started in June 1968, when I traveled from Lebanon to New York to begin my fellowship in medical oncology at Memorial Sloan Kettering Cancer Center. Since then, and on a daily basis, I have been actively engaged in the treatment of patients with cancer and in cancer...
The Story of Three Patients With Leukemia
The human drama within the oncology world is a never-ending story of triumph, tragedy, and all of the valiant efforts and human emotions in between. The doctor-patient relationship in oncology is deeper and longer than in most medical specialties due to the life-and-death stakes at play after a...
Ancestry and Molecular Makeup of Cancer Evaluated in New Study
A new study by researchers from the National Cancer Institute (NCI) Cancer Genome Analysis Network, a collaborative group with investigators in the United States, Canada and Europe, provides the most comprehensive look to date at the effect of ancestry on the molecular makeup of normal and...
Gynecologic Oncologist Describes His New Normal in a New York Hospital
During the COVID-19 pandemic, The ASCO Post will be interviewing oncologists on how they and their centers are dealing with the crisis. Here, we speak with Alexander Melamed, MD, MPH, a gynecologic oncologist and Assistant Professor of Obstetrics & Gynecology at NewYork-Presbyterian/Columbia...
Indiana University Researcher Receives $1.6 Million NCI Grant for Multiple Myeloma
G. David Roodman, MD, PhD, of Indiana University (IU) Melvin and Bren Simon Comprehensive Cancer Center, has been awarded a 5-year, $1.6 million grant from the National Cancer Institute (NCI) to study ways to build bone and decrease tumor growth in multiple myeloma bone disease. Dr. Roodman is...
Sleeping Well After Cancer: Patient-Centered Research for Treatment of Insomnia
Insomnia is a persistent sleep disorder that affects nearly 60% of people with cancer, diminishing their quality of life.1,2 Chronic insomnia disorder is defined by trouble falling asleep, staying asleep, or waking too early three times per week for 3 months or more.3 Standard care comprises...
Is Estrogen Protective Against COVID-19?
Reports suggest that the severity of coronavirus infection may be significantly more pronounced in men than in women.1 Studies have demonstrated that estrogen reduces both influenza virus replication in human female nasal epithelial cells2 and moderates the cytokine storm in murine models of this...
Treating Patients With Leukemia During the COVID-19 Era at MD Anderson Cancer Center
As part of a series of interviews with cancer experts during the COVID-19 pandemic, The ASCO Post spoke with Hagop Kantarjian, MD, Professor and Chair of the Department of Leukemia at The University of Texas MD Anderson Cancer Center, Houston, about the impact of the pandemic on treatment of...
NIH Aims to Quantify Undetected Cases of Coronavirus Infection
A new study has begun recruiting at the National Institutes of Health (NIH) in Bethesda, Maryland, to determine how many adults in the United States without a confirmed history of infection with SARS-CoV-2, the virus that causes COVID-19, have antibodies to the virus. The presence of antibodies in...
OneOncology Names Jeff Patton, MD, Chief Executive Officer
Jeff Patton, MD, has been named Chief Executive Officer of OneOncology, a national partnership of independent community oncologists. Dr. Patton has been Acting Chief Executive Officer and President of Physician Services since February. Dr. Patton will continue as Executive Chairman of the Board of ...
Melanoma Research Alliance Announces $11 Million for Grant Awards
In recognition of Melanoma Awareness Month, the Melanoma Research Alliance has announced funding for 26 research awards, totaling $10.9 million. These grant awards are made possible through the significant contributions of individuals, families, institutions, and corporate allies. The 26 awards...
Despites Advances, Treatment-Related Sequelae Remain Problematic in Pediatric Neuro-oncology
The management of pediatric brain and spinal cord tumors is extremely complex, as are the survivorship issues in this highly vulnerable patient population. To shed light on the current clinical reality in this setting, The ASCO Post recently spoke with Katherine E. Warren, MD, an internationally...
Being Interviewed on Zoom? Here Are Some Professional Tips
You’ve agreed to be interviewed on Zoom. If you’re like most people, the technology itself isn’t a barrier. (And if it is, you can consult our step-by-step guide to using Zoom at https://bit.ly/2yxcTN0.) However, you might be less sure about what you can do to make the best impression (and the most ...
How California Dreamer John Craig Venter, PhD, Changed Paths to Focus on Sequencing the Human Genome
In this edition of the Living a Full Life series, guest editor Jame Abraham, MD, FACP, spoke with John Craig Venter, PhD, Founder, Chairman, and Chief Executive Officer of the J. Craig Venter Institute, a nonprofit organization dedicated to human, microbial, and environmental genomic research. A...
How the COVID-19 Pandemic Is Propelling the Delivery of Home Care for Patients With Cancer
In 2019, the Penn Center for Cancer Care Innovation at the University of Pennsylvania’s Abramson Cancer Center began planning a demonstration program, called Cancer Care at Home, to broaden the delivery of oncology treatments to patients in the home setting. The existing services offered by Penn...
Tucatinib in Previously Treated HER2-Positive Metastatic Breast Cancer
On April 17, 2020, tucatinib was approved for use in combination with trastuzumab and capecitabine for treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. These patients included those with brain metastases and those who have received one or more prior...
Mitomycin Gel for Low-Grade Upper Tract Urothelial Cancer
On April 15, 2020, mitomycin gel was approved for the treatment of adult patients with low-grade upper tract urothelial cancer.1,2 Mitomycin gel is for pyelocalyceal use alone and not for intravenous, topical, or oral administration. Supporting Efficacy Data Approval was based on findings in the...
Genetics May Soon Guide Targeted Treatment of Brain Metastases
Genetic mapping of brain metastases, in the laboratory of Priscilla Brastianos, MD, Director of the Central Nervous System Metastasis Center at Massachusetts General Hospital/Harvard Medical School, and Scott Carter, PhD, at the Harvard School of Public Health, is yielding findings that could...
Luspatercept-aamt for Anemia in Adults With Myelodysplastic Syndromes
On April 3, 2020, luspatercept-aamt was approved in the treatment of anemia failing to respond to an erythropoiesis-stimulating agent and requiring 2 or more red blood cell (RBC) units over 8 weeks.1,2 The treatment is geared toward adult patients with very low– to intermediate-risk myelodysplastic ...
Selumetinib for Pediatric Neurofibromatosis Type 1 With Symptomatic, Inoperable Plexiform Neurofibromas
On April 10, 2020, the oral MEK inhibitor selumetinib was approved for the treatment of patients 2 years of age and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas.1,2 Selumetinib is the first therapy approved for children who have this disease....
